The Pharma Data

MAY 1, 2023

In response, WHO, together with global partners and experts, took the leadership in developing a global strategy that sets forth a vision and roadmap to defeat meningitis by 2030. In November 2020, this global roadmap on meningitis was approved by the Seventy-Third World Health Assembly (resolution WHA73.9).

Treatment 40

Treatment Government Vaccine International 40

biobide

DECEMBER 1, 2023

Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.

Treatment 97

Treatment Production Marketing Research 97

Drug Discovery World

APRIL 11, 2024

COPD currently has limited treatment options despite being a leading cause of death globally. By 2030, it’s estimated that the global cost of COPD will rise to $4.8 trillion by 2030 1 , indicating a serious unmet need for new and improved therapeutics. ” 1: The Global Economic Burden of Noncommunicable Diseases.

Therapies 130

Therapies Clinical Trials Disease Trials 130

Drug Discovery World

JUNE 3, 2024

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccine 148

Vaccine Trials Clinical Trials Hospitals 148

Drug Discovery World

APRIL 14, 2023

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

JULY 16, 2024

The World Health Organization has announced a goal of reducing the global burden of snakebite in half by 2030. However, current antivenom treatment is expensive and does not effectively treat the necrosis of the flesh where the bite occurs.

Science 130

Science Treatment Drugs Disease 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

Drug Discovery World

DECEMBER 7, 2023

Despite recent leaps forward in our understanding of MND biology, treatment options remain limited. MND drug repurposing fund The fund is part of LifeArc’s multi-million pound Motor Neuron Disease Translational Challenge to make MND treatable by 2030 and ultimately find a cure. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Clinical Trials Drugs Trials 130

Drug Discovery World

MARCH 13, 2023

Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility,” said Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma.

Trials 130

Trials Clinical Trials Laboratories Clinical Development 130

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Production 52

Drug Discovery World

MAY 31, 2024

billion by 2030, according to a market research report by Market Research Future. ” The US schizophrenia market is projected to grow to $8.06 The drug has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.

Licensing 148

Licensing Licensing FDA Approval Drugs 148

Drug Discovery World

OCTOBER 18, 2023

We’re beginning to see their potential come to fruition, with the FDA having approved three treatments as of January 2023 — for retinal dystrophy 1 spinal muscular atrophy, 2 and haemophilia B. Consequently, researchers are progressing treatments that are unlikely to succeed at clinical trials, while rejecting potentially powerful ones.

Therapies 163

Therapies Clinical Trials FDA Approval Virus 163

Drug Discovery World

FEBRUARY 28, 2023

This funding follows a £360K ($435K) Biomedical Catalyst grant from Innovate UK, awarded to FAB early in 2022 to develop its technology as a treatment for chronic wounds. billion by 2030. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, as well as other Angel investors, with support from KPMG Acceleris.

Small Molecule 130

Small Molecule Disease Science Treatment 130

Drug Discovery World

APRIL 16, 2024

SEALS is a double-blind, randomised, placebo-controlled, multicentric Phase II study that will assess the efficacy, safety, tolerability and pharmacokinetics of NX210c treatment in ALS patients. Part of the study is supported by the Region Auvergne-Rhône-Alpes and the French Government through i-Demo Régionalisé, a France 2030 grant.

Clinical Trials 130

Clinical Trials Trials Pharmacokinetics Drugs 130

Drug Discovery World

MAY 22, 2023

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease.

Disease 130

Disease Clinical Trials Laboratories Treatment 130

Drug Target Review

SEPTEMBER 21, 2023

The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. With accessible and effective treatments, this is feasible. doi: 10.1002/14651858.CD011146.pub2.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

MAY 26, 2023

The new list also includes secondary prevention for rheumatic fever, acute and long-term management of asthma and chronic obstructive pulmonary disease as well as several cancer control interventions related to cervical, breast, colorectal, liver and childhood cancer, and the comprehensive treatment of cancer for those living with HIV.

Disease 52

Disease Government Treatment Production 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

JULY 31, 2023

Despite a range of treatments for heart failure, Dr Streefkerk argues that there are still a lot of patients dying or ending up in hospital due to the condition. But despite high levels of research, treatments are still limited and surgical interventions are commonplace for many heart conditions. million people every year.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

Drug Discovery World

OCTOBER 6, 2022

until 2030. It is therefore not surprising that Switzerland played an important role in the global effort to combat the pandemic, and that two Swiss based companies were successful in developing treatments to combat Covid infections (Humabs BioMed/Vir Biotechnology and Molecular Partners/Novartis).” . Valued at $14.8

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. With sales soaring to $2.2 for this class of drugs.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

New Drug Approvals

JANUARY 31, 2024

The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

NOVEMBER 2, 2020

billion cumulative treatments to more than 923 million people since 2000. The treatments target the parasites in the blood of infected people and prevent the risk of transmission in the community. Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

Drug Discovery World

JANUARY 2, 2024

He said: “Between now and 2030, we’re going to see a range of vaccines using various technologies. However, she believes perhaps the biggest issue with treatment development is simply: it takes too long. As for Infinitopes, the company’s trials will begin in 2024. She said: “The speed is not sustainable.

Research 148

Research Vaccine Science Trials 148

FDA Law Blog: Biosimilars

JULY 10, 2024

Using PGHD can help patients manage their own health and can help sponsors develop endpoints for studying impacts of new treatments that matter to patients. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030.

Clinical Trials 59

Clinical Trials Regulations Trials Treatment 59

The Pharma Data

APRIL 12, 2022

per person per year from now until 2030. This investment would realize more than US$ 230 billion in economic and societal benefits and avert nearly 10 million heart attacks and strokes globally by 2030. NCDs are largely preventable and treatable, nearly 7 million lives could be saved for just US$ 0.84

International 52

International Disease Government Production 52

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. Nat Rev Bioeng [Internet]. 2023 Jan 19;1(1):32–45. 95: 729–38

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Goldman Sachs analysts anticipate a significant rise in the number of U.S.

Pharmaceutical Companies 81

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 81

The Pharma Data

NOVEMBER 1, 2020

billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. According to Frost & Sullivan analysis, global market of MS drugs reached US$23.0 billion in 2018, and it is expected to be up to US$48.9

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

The Pharma Data

MAY 15, 2023

The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met its 2023 targets to train employees on compliance policies.

Government 40

Government Compliance Pharmaceuticals Production 40

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 130

Drugs Engineering Clinical Trials Science 130

The Pharma Data

MARCH 11, 2021

Roche is committed to helping countries scale up HIV elimination programs and reach the WHO 2030 goals of 95% of people living with HIV knowing their HIV status; 95% of HIV-positive people on treatment; and 95% of people on treatment having suppressed viral loads. About the Global Access Program.

Disease 52

Disease Laboratories Treatment Virus 52

The Pharma Data

APRIL 7, 2021

Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. Leveraging R&D efforts to address crucial treatment gaps. Pushing to build more diverse and inclusive workforce.

Packaging 52

Packaging Vaccine Disease Treatment 52